GIPR antagonist antibodies conjugated to GLP-1 peptide are multispecific molecules that decrease weight in obese mice & monkeys
Les Miranda
Executive Director, R&D & CMC Operations, Amgen
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate glucose and energy homeostasis. Targeting both pathways with GIP receptor (GIPR) antagonist antibody (GIPR-Ab) and GLP-1 receptor (GLP-1R) agonist, by generating GIPR-Ab/GLP-1 multispecific molecules, is an approach for treating obesity and its comorbidities. In mice and monkeys, these multispecific molecules reduce body weight (BW) and improve many metabolic parameters. Overall, these GIPR-
Ab/GLP-1 molecules promote BW loss, and they may be used for treating obesity.
Over 20 years of Research and Operations experience in developing innovative therapeutic candidates spanning RNA, biologics, peptide, and small molecule modalities focusing on the areas of metabolic disease, neurobiology, hematology, oncology, and inflammation; leading to the filing of >19 Investigational New Drug (IND) applications to advance life-changing medicines for patients, >50 peer-reviewed top-tier publications, and an inventor on 30 public domain patent applications including AMG 133. Extensive scientific experience in diverse therapeutic modality & technology platforms for peptides, oligonucleotides (RNA), biologics, T-cell engagers, multi-specifics, antibody-peptide conjugation, ADCs, and small molecules involving RNA-based screening technologies, analytical chemistry, structural biology, computational chemistry, laboratory automation, and data science. Strong executive experience and presence in facility and staff management (>75 FTEs, >$25M budget); organizational transformation; early pipeline review; product & technology licensing;, acquisitions; and venture investment. Experienced public speaker at international scientific events, and co-chair for the Gordon Research Conference (GRC), Chemistry & Biology of Peptides, and the 27th American Peptide Symposium.